Tejs Ehlers Klug

Gubra is a Danish biotechnology company that operates a unique hybrid business model, combining high-end pre-clinical contract research services (CRO) with a proprietary pipeline of peptide-based drug candidates. Founded in 2008 and headquartered in Hørsholm, the company specializes in metabolic and fibrotic diseases, particularly obesity, MASH, and diabetes. Gubra utilizes its proprietary stREPT platform and advanced machine learning capabilities to accelerate the discovery of novel peptide therapeutics. Their most advanced programs include partnerships with major pharmaceutical companies like Boehringer Ingelheim, notably for the development of survodutide, a dual GLP-1/glucagon receptor agonist. The company is listed on the Nasdaq Copenhagen exchange and continues to expand its internal pipeline while providing specialized research services to the global pharmaceutical industry.